Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Despite advancements in ultra-fast and ultra-long-acting insulins, there has been a paucity of new non-insulin glucose-lowering therapies specifically licensed for type 1 diabetes
These drugs use peptides that mimic natural satiety hormones in our bodies
An excess of this medication can lead to severe hypoglycemia, nausea, vomiting, and abdominal pain among other symptoms, and these symptoms can be dangerous if not treated promptly and properly
What's often left out of the headlines: most participants started the trials clinically obese and ended them still clinically obese, just less so
It is FDA-approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities
Especially since GLP-1 agonists now have been shown to alter taste and tactile perception in some users
